patients candidat for CT-Scan by contrast media. Other and unspecified disorders of circulatory system
Conditions
Interventions
Intervention 1: Intervention: Patients in this group based on randomization will receive a single dose Opaquesol of Shahid Ghazi with dosage of 300 mg. Intervention 2: Control: Patients in this group
Diagnosis
Intervention: Patients in this group based on randomization will receive a single dose Opaquesol of Shahid Ghazi with dosage of 300 mg.
Control: Patients in this group based on randomization will receive a single dose Omnipaque with dosage of 300 mg.
Sponsors
Shahid Ghazi Pharmaceutical Company
Eligibility
Sex/Gender
All
Age
45 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients aged between 45 to 65 years old; Referred subjects for CT-Scan by contrast media; Provided signed and dated informed consent subjects. Exclusion criteria: Patient with contrast administration in the past 7 days; Subjects have known contra-indication and allergy to contrast administration; Renal insufficiency as defined by GFR < 50; Lactation; Pregnancy; Bronchial asthma; Clinical unstable condition (hemodynamic, respiratory, neurologic); Emergency cases; Hyperthyroidism; End-stage patients.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Image quality. Timepoint: after CT-Scan. Method of measurement: 1 to 10 scoring by investigator. | — |
Secondary
| Measure | Time frame |
|---|---|
| Renal Toxicity. Timepoint: Before and 72 hours after injection. Method of measurement: Serum creatinine.;Adverse events of contrast media. Timepoint: During injection, 4 and 72 hours after injection. Method of measurement: Interviewing with patient. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Ramin Heshmat
Head of Chronic Diseases Research Center
Outcome results
None listed